Sign up for Breaking News Email Alerts


Investor Center

Recent Presentations
Investor Presentation – May 2013 - Adobe PDF Investor Presentation – May 2013
Webcast ImageLive Streaming Video:
Thursday, May 23, 9:05 a.m. EST / 2:05 p.m. UKT Neuralstem, Inc. at 8th Annual World Stem Cells & Regenerative Medicine Congress 2013
Corporate Profile

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. The company received FDA approval to commence a Phase II NSI-566 clinical trial for ALS in April 2013, and was approved in January 2013 to commence a Phase I NSI-566 safety clinical trial for chronic spinal cord injury (cSCI). Neuralstem is targeting additional major CNS conditions with its cell therapy platform, including ischemic stroke, glioblastoma (brain cancer), and Huntington’s disease.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some CNS conditions. The company is in an FDA-approved Phase Ib safety trial evaluating NSI-189, its first of four neurogenic small molecule compounds, for the treatment of major depressive disorder. The FDA approved dosing of the third and final cohort of depression patients in April 2013. Additional indications could include traumatic brain injury, Alzheimer's disease, and post-traumatic stress disorder (PTSD).

CUR (Common Stock)
Price$1.49
Change (%) Stock is Up 0.04 (2.76%)
Volume2,133,474
05/17/13 4:00 p.m. ET
Full Stock Quote
Minimum 20 minute delay
Refresh quote
Contact Information

Investor Relations
MDC Group
David Castaneda | 414.351.9758
Susan Roush | 818.222.8330

Neuralstem, Inc. Headquarters
9700 Great Seneca Highway
Rockville, MD 20850
301.366.4960

Recent NewsMore >>
DateTitle 
05/16/13Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London
ROCKVILLE, Md., May 16, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President, Richard Garr, will present at the Annual World Stem Cells and Regenerative Medicine Congress on Thursday, May 23, in London, UK.  Mr. Garr's talk, "Understanding the Practicalities of Using Innovative Therapies on Patients," at 2:05 PM, will explore how cell therapies will be used by clinicians and integrated into hospital settings (http://www.terrapinn.com/2013/stemcells/spe... 
Download PDF
05/13/13Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress
ROCKVILLE, Md., May 13, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that Eva Feldman, MD, PhD, principal investigator, will present updated Phase I data from the trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the Romanian Neurological Society Congress held in Bucharest, Romania, on May 17th.  In a talk called "Recent Therapeutic Advances in Stem Cell Therapy," Dr... 
Download PDF
05/10/13Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
ROCKVILLE, Md., May 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2013 and provided a business and clinical update. "The Company continues to progress all of its clinical trial programs, in the U.S. and abroad, as we move into 2013. The FDA has approved our Phase II trial protocol for NSI-566/ALS, which we expect to initiate this summer. The protocol calls for an aggressive dose escalation strategy and a... 
Download PDF
05/08/13Neuralstem ALS Trial Investigator And Patient On Sirius XM
Dr. Eva Feldman and Ted Harada to discuss Neuralstem ALS Trial ROCKVILLE, Md., May 8, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will be a guest on Sirius XM's Doctor Radio station, channel 81, on Thursday, May 9, 10-11am EDT. Dr. Feldman will be on "Beyond th... 
Download PDF
Upcoming EventsMore >>
DateDescription
Friday,
May 17, 2013
Neuralstem NSI-566/ALS Principal Investigator at Romanian Neurological Society Congress
Speaker: Eva Feldman, MD, PhD
Location: Bucharest, Romania
Title:

“Recent Therapeutic Advances in Stem Cell Therapy”

DateDescription
Thursday,
May 23, 2013
2:05pm UKT
Neuralstem, Inc. at 8th Annual World Stem Cells & Regenerative Medicine Congress 2013
Speaker: Richard Garr, President and CEO
Location: London, UK
Title:

“Understanding the Practicalities of Using Innovative Therapies on Patients”


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Privacy and Terms ©Neuralstem, Inc. 2013